



Int Poster J Dent Oral Med 2002, Vol 4 No 1, Poster 112

A Phase II Trial of Concurrent Paclitaxel, Carboplatin and Radiotherapy in Stage III/IV Resectable Cancer of the Oral Cavity and Oropharynx

Language: English

Authors: Christian Küttner MD DDS¹, André Eckardt MD DDS¹, D. Rades MD², Ingeborg Wildfang MD², Christof Hofele MD DDS³, Ralf Dammer MD DDS⁴

- ¹Hannover University Hospital, Department of Oral & Maxillofacial Surgery
- ²Hannover University Hospital, Department of Radiotherapy
- ³University Hospital Heidelberg, Department of Oral & Maxillofacial Surgery
- ⁴University Hospital Regensburg, Department of Oral & Maxillofacial Surgery

Date/Event/Venue:

3. - 23.03.2000 24. Deutscher Krebskongress

Introduction

Berlin

In the treatment of head and neck cancer chemotherapy used to be limited to metastatic or recurrent settings. During the last twenty years the addition of chemotherapy to aggressive local treatment has been investigated to overcome high local relapse rates. Recent meta-analysis have confirmed data of randomized trials of combined modality treatment concepts and identified the advantage in treatment outcome for patients with concomitant chemoradiotherapy (Munro 1995, El-Sayid et al. 1996, Bourhis et al. 1998). Many chemotherapeutic agents have been used as radiation sensitizers, including platinum compounds, bleomycin, mitomycin, and antimetabolites such as methotrexate and 5-fluoro-uracil. Taxane have been the focus of several multi-modality studies combining chemotherapy and radiotherapy (Aisner et al. 1995, Hoffmann et al. 1996, Chougule et al 1997, Vogt et al. 1998). The efficacy and feasibility of a Paclitaxel/Carboplatin combination with simultaneous radiotherapy could be demonstrated in phase I-II trials (Tab.1).

	pts	operability	Regimen	Response
Chougule (1997)	34	operable	Paclitaxel 60mg/m ² Carboplatin AUC 1 Radiation 45Gy	CR 73% PR 23% pCR 71% (PT) pCR 85% (LN)
Chougule (1997)	16	inoperable	Paclitaxel 60mg/m ² Carboplatin AUC 1 Radiation 72Gy	CR 57% PR33%
Haas (1999)	60	inoperable	Paclitaxel 45mg/m ² Carboplatin 100mg/m2 Radiation 72Gy	CR 82% PR 11%

Tab. 1

Both Paclitaxel and Carboplatin have demonstrated high single agent activity in head and cancer as well as radiosenzitizing effects (Hoffmann et al.1996, Leonard et al.1997). Paclitaxel causes a enhancement of the rate and yield of microtubular assembly and prevents microtubular depolimerisation, therefore acting as a mitotic inhibitor in the radiation-sensitive G2/M-phase. Based on documented excellent radiosensitization effects, a prospective phase II trial was initiated using Paclitaxel (P) and Carboplatin (C) with concurrent conventional fractionated radiotherapy followed by surgery of the primary tumor and regional neck nodes.

Methods

Patients were eligible for this study if they met the following criteria: histologically confirmed squamous cell carcinoma of the oral cavtiy or oropharynx; resectable stage III and IV disease; ECOG performance status <2; no tumor-specific pretreatment; no major impairment of liver, kidney, bone marrow, lung, or cardiovascular functions. Staging procedures consisted of careful clinical investigation with tattoowing of the resection margins under general anesthesia, neck sonography, computed tomography of the primary lesion and the neck, chest x-ray. The extent of the disease was defined according to the TNM system.

Radiotherapy was applied using a conventional fractionated protocol of 5×2.0 Gy/week to a total dose of 40Gy with 6-MeV photons. Using standard premedication Paclitaxel 40mg/m2 was administered as a weekly continuous 1-hour infusion in weeks 1-5, followed by Carboplatin AUC 1,5 continuous infusion over 30 minutes. Colony-stimulating factors were given only in instances of severe neutropenia with documented infection. Toxicity was grade according to the NCI Common Toxicity Criteria (CTC); and response was assessed according to WHO standards.

Surgery of the primary tumor followed within four weeks after completion of chemoradiation. Resection of the tumor, a suprahyoidal or complete functional neck dissection was performed according to DÖSAK criteria. The mucosal defects were reconstructed in most cases using a fasciocutaneous radial forearm flap.

This study was approved by the ethics committee of our institution. Written informed consent was required from all patients. All patients underwent repeated clinical examination during treatment for identification of response and acute reactions.

Results

From 5/98 to 10/99 twenty-eight patients (23 males, 5 females) with stage III (6 pts.) and stage IV (22 pts.) desease were enrolled. The mean age was 54 years (range 40-71). Six patients had squamous cell carcimona of the oropharynx and twenty-two patients of the oral cavity.

A total of 115 cycles of chemotherapy was administered to the patient population. Patients data of this ongoing trial are summarized in Tab. 2.

Treatment period:	5/98 - 10/99
	No.of pts
Total	28
Female	5
Male	23
Tumor site:	
Oral cavity	22
Oropharynx	6
Median age	54 yrs (range 40-71)
T-Stage:	
T1	0
T2	6
T3	9
T4	13
N-Stage:	
NO	5
N1	10
N2	13
N3	0
Stage III	6
Stage IV	22

Tab. 2

Twenty-seven patients were evaluable for toxicity and response (Tab.3). One early death was reported due to septic neutropenia. Clinical response was as follows: CR (14/27 52%); PR (13/27 48%).

Response rates			
evaluable:	27/28 pts		
CR	52% (14/27)		
PR	48% (13/27)		
pCR	44% (10/23)		
pPR	56% (13/23)		

Tab. 3

CTC grade 2 or 3 mucosistis occured in all patients. Hematologic toxicity was as follows: hemoglobin CTC grade 3 (14%), leukocytes CTC grade 1 (24%), grade 3 (33%), grade 4 (10%), thrombocytes CTC grade 2 (10%), grade 3(14%).

	Mucosa	
	weeks 1-2	weeks 3-4
grade 0	8%	0%
grade 1	63%	8%
grade2	29%	63%
grade3	0%	29%
	Skin	
	weeks 1-2	weeks 3-4
grade 0	54%	0%
grade 1	42%	63%
grade 2	4%	33%
grade 3	0%	4%

Tab. 4

Major non-hematologic toxicity was mucositis and dermatitis (Tab.4). Median value of leucocytes, hemoglobin, and thrombocytes are shown in Fig.1a-c. Twenty-three patients were evaluable for pathologic response after surgical resection. Pathological response was as follows: pCR (10/23 44%); pPR(13/23 56%). With a median follow-up of 10 months the 1-year-survival is 88% (Tab.5)




Fig. 1a: Leucocytes




Fig. 1b: Hemoglobin




Fig. 1c: Thrombocytes

	Follow up	
Median follow-up	10 months	range 5 - 20 Mo
1-year-survival	88%	
local recurrence (neck node)	1	after 4 months
treatment-related death	1	septic neutropenia
post-operative death	1	pneumonia

Tab. 5

Conclusion

The prognosis of advanced squamous cell carcinoma of the head and neck remains poor. Concurrent P/C and radiotherapy resulted in excellent clinical and pathological response rates in advanced stage disease (pCR 44%, pPR 56%). Mucositis was the most common and significant toxicity. The treatment can be performed on outpatient basis. The present phase II trial preceeds a randomized study of the DÖSAK Cooperative Group.

References

- AisnerJ, Belani CP, Kearns C, Conley B, Hiponia D, Engstrom C, Zuhowski E, Egorin MJ: Feasibility and pharmacokinetics of paclitaxel, carboplatin, and concurrent radiothrapy for regionally advanced squamous cell carcinoma of the head and neck and for regionally advanced non-small cell lung cancer Sem Oncol, 1995, 22(Suppl12), S.17-21
- Bourhis J, Pignon JP, Designe L, Luboinski M, Guerin S, Domenge D: On behalf of the MACH-NC Collaborative group: Metaanalysis of chemotherapy in head and neck cancer (MACH-NC):Loco-regional treatment vs same treatment + chemotherapy (CT)
 - Proc Am Soc Clin Oncol, 1998, 17, S.386a
- 3. El-Sayed, S, Nelson N: Adjuvant and adjubctive chemotherapy in the management f squamaous cell carcinoma of the head and neck region: A meta-analysis of prospective and randomized trials J Clin Oncol, 1996, 14, S.838-847
- 4. Hoffmann W, Heinrich V, Belka C, Budach W, Schmidberger H, Bochtler H, Rodemann, Bamberg M: Präklinische und klinische Ergebnisse in der simultanen Radiochemotherapie von Kopf-Hals-Tumoren mit Paclitaxel Strahlenther Onkol, 1996, 172, (Suppl I), S.15-20
- 5. Leonard CE, Chan CD, et al.: Paclitaxel enhances in vitro radiosensitivity of squamous cell carcinoma cell lines of the head and neck
 - Cancer Res, 1997, 56, S.5198-520
- Munro A: An overview of randomized controlled trials of adjuvant chemotherapy in head and neck cancer Brit J Cancer, 1995, 71, S.83-91
- Vogt HG, Martin T, Capizello A, Kolotas C, Hey S, Schneider L, Dornoff W, Fountzilas G, Templin T, Kettner H, Zamboglou N: Concurrent Paclitaxel and Radiotherapy - Treatment Feasibility Studies Strahlenther Onkol, 1998, 174(Suppl I), S.24-28
- 8. Eckardt A, Wildfang I, Karstens JH: Simultane Radiochemotherapie mit Taxol/Carboplatin bei fortgeschrittenen, operablen Kopf-Hals-Tumoren Vorläufige Ergebnisse Strahlenther Onkol, 1999, 175(Suppl III), S.11-13

Correspondence address:

Christian Küttner MD DDS

Medizinische Hochschule Hannover Mund-Kiefer-Gesichtschiruraie Carl-Neuberg-Str. 1 30625 Hannover Germany

Poster Faksimile:



A PHASE II TRIAL OF CONCURRENT PACLITAXEL, CARBOPLATIN AND RADIOTHERAPY IN STAGE III/IV RESECTABLE CANCER OF THE ORAL CAVITY AND OROPHARYNX

C. Nuettner¹, A. Eckardt¹, D.Rades², I. Wildfarg², C.Rufele³, R.Dammer⁴

Introduction

Introduction
in the treatment of bead and neck concer chemistrancy
and to be limited to methadatic or recurrent actings.
During the had weary years the additions of chemistrancy
to be aggressive band to material has been involugiant to
the aggressive band to material has been involugiant to
the configuration of the control of the control
town configuration of the control
town configuration of the control
town configuration of the control
town control of the control
town control of the control
town contr oten the toess of several milli-modality filiables combing themsterropy and radiatherapy (Aliser et al. 1995; Bolfmann et al. 1996; Chougele et al. 1997; Vogt et al. 199%). The efficiery and feasibility of a Pacificaci Cultuplatin conhination with simultaneous radiatherapy oxidi be demonstrated in phase 1-tl trials (Tale.1).



Both Pacifixed and Carlephris have demonstrated high single agent activity in lead and concer as well as reali-serationing effects (Roffmans et al. 1996; Lennard et al. 1997). Parliance causes a enhancement of the rate and particularly activated and particular activated and particular activated and particular activates and particular activates and particular activates and the realistic according to the particular activates and particular and incensibilities of Efects, a prospective phase II sould was milited using Pacificat (P) and Carlephris (C) with concurrent conventional fractionstate academorary followed by surpays of the primary tumer and regional each node.

Methods

Methods

Attents were eligible for this study if they met the following release histologically confirmed squarmon cell customines of the end untily or emphasying, resterbile staps III and IV desires. EOOG profitments eithers 4-7, an utransequently prefestationals no major impairment of lives, kilary, hone merros, limp, or enrichwestell frame-items. Stapsing procedures consisted of careful elisical workingston with attentioning of the resterlism menginister general amofilexis, next, knotography, computed unmangsafuly of the primary lesions and the next, death a vay, The extent of the disease was defined according to the TSMM system.

to the part of the plant of the control of the cont

Sugary of the primary lumor followed within fear weeks after completion of chemoralistics. Resocion of the lumor, a superhysidal or complete function and efforts on the primary sugarbapidal or complete function and defects were reconstructed in most cases using a faciocutionous radial freezam feets, committee of our institution. White information of the original primary superior from all priesters. All patients underwood superior distribution of the primary to the primary for the primary superior for superior for the primary superior for the primary superior for th

Results

Results
Tom 50% to 10392 twesty-sight patients (23 malus, femalies) at 10392 twesty-sight patients (23 malus, femalies) with stage III (6 pts.) and stage IV (22 pts.) and stage IV (22 pts.) as the stage was been partially as the stage was been paraphary, and I the temperature and interest, when patients of the end easily. A total of 118 cyclin of shortesteragy was administrated to the patient population. Patients data of this ongoir Irial are manuscrated in Tale, 2.




52%); PR (13/27 48%),



CTC grade 2 or 3 muonistis occored in all patient Humatologic torticity was as follows hemoglobus CT grade 3 (1486), feakneytes CTC grade 1 (2486), grade (33%), grade 4 (1086), Hembucytes CTC grade 2 (189) grade 3 (1486).

- A.C.	Bullion	ersy (direct	1
	Application of the last	10000	
SEADON N	- 10	11.	
SCHOOL S	308.	49	
MWW.	200	100	
place?	28	199	
	and a line		
Grade III	644	14	
of solin 6	829	110	
DE NOTE D	49	149	
or little in	3.9	144	



State billion on	III mode	mage 1 < 11 for
T-processories	1111	
	0 0	-
	. 0	-
	0.00	Service .

LONCLUSION
It proposes of advanced squaress cell continues of the hard and neck remains post. Concirent IVE and real-tive proposes of the excellent release and published and propose parts in advanced stage disease [pCR 44%, PER 978]. Miscottis was the most common said spindoman widely. Miscottis use the sinest common said spindoman ricidly. The textiment can be proformed on estipation with the proposed parts of the proposed of the pro-tone for proposed place. The proposed is a randomized today of the DBSAK Compensive Group.